Okada Yosuke, Tanaka Yoshiya
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Clin Calcium. 2014 Nov;24(11):1689-94.
A lifestyle-related disease and osteoporosis are diseases to increase with aging and a lifestyle-related disease has an influence on the bone metabolism. Because the number of patients with lifestyle-related disease is getting larger, it is necessary to prevent fracture in those. Unfortunately, substantial randomized control studies are yet to be done in patients with lifestyle-related disease to clarify if anti-osteoporotic drugs are effective to prevent fractures. It is suggested by the subanalysis in the existing clinical study with usefulness of bisphosphonates with evidence as an osteoporotic therapeutic drug in life-related disease. Here I will review about the effective and problem with bisphosphonate for the lifestyle-related disease with arteriosclerosis.
生活方式相关疾病和骨质疏松症是随年龄增长而增加的疾病，生活方式相关疾病会影响骨代谢。由于生活方式相关疾病的患者数量不断增加，有必要预防这些患者发生骨折。遗憾的是，尚未对生活方式相关疾病患者进行大量随机对照研究，以阐明抗骨质疏松药物预防骨折是否有效。现有临床研究的亚分析表明，双膦酸盐作为生活方式相关疾病中的骨质疏松治疗药物具有有效性证据。在此，我将综述双膦酸盐治疗动脉硬化相关生活方式疾病的有效性和问题。
